Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
75%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (25.0%)
N/A3 (75.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Prospective Clinical Surveillance With Application of Trigger Tools in Critically Ill Patients

NCT03781713
completednot_applicable

The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow

NCT02146404
completednot_applicable

Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125

NCT01436734
completednot_applicable

The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity

NCT00160056

Clinical Trials (4)

Showing 4 of 4 trials
NCT03781713Phase 2

Prospective Clinical Surveillance With Application of Trigger Tools in Critically Ill Patients

Completed
NCT02146404Not Applicable

The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow

Completed
NCT01436734Not Applicable

Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125

Completed
NCT00160056Not Applicable

The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4